Stockholm, Sweden, October 1, 2010
During August, 195,575 new B shares were issued in Elekta through the exercise of warrants distributed within the framework of the established option program.
The total number of shares in Elekta at the end of September amounts to 93,755,946 divided between 3,562,500 A shares and 90,193,446 B shares.
One Series A share entitles the holder to 10 votes and one Series B share to one vote.
Elekta’s current holding of own shares amounts to 502,000 B shares, repurchased during June 2010.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com (http://www.elekta.com/).